GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cartesian Therapeutics Inc (NAS:RNAC) » Definitions » Cyclically Adjusted PS Ratio

RNAC (Cartesian Therapeutics) Cyclically Adjusted PS Ratio : 0.65 (As of May. 30, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Cartesian Therapeutics Cyclically Adjusted PS Ratio?

As of today (2025-05-30), Cartesian Therapeutics's current share price is $9.56. Cartesian Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $14.70. Cartesian Therapeutics's Cyclically Adjusted PS Ratio for today is 0.65.

The historical rank and industry rank for Cartesian Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:

RNAC' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.62   Med: 1.23   Max: 1.64
Current: 0.65

During the past years, Cartesian Therapeutics's highest Cyclically Adjusted PS Ratio was 1.64. The lowest was 0.62. And the median was 1.23.

RNAC's Cyclically Adjusted PS Ratio is ranked better than
87.7% of 496 companies
in the Biotechnology industry
Industry Median: 5.365 vs RNAC: 0.65

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Cartesian Therapeutics's adjusted revenue per share data for the three months ended in Mar. 2025 was $0.042. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $14.70 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Cartesian Therapeutics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Cartesian Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cartesian Therapeutics Cyclically Adjusted PS Ratio Chart

Cartesian Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 1.20

Cartesian Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 1.05 1.20 0.90

Competitive Comparison of Cartesian Therapeutics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Cartesian Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cartesian Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cartesian Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cartesian Therapeutics's Cyclically Adjusted PS Ratio falls into.


;
;

Cartesian Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Cartesian Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=9.56/14.70
=0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cartesian Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Cartesian Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.042/134.9266*134.9266
=0.042

Current CPI (Mar. 2025) = 134.9266.

Cartesian Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 2.881 100.684 3.861
201509 3.746 100.392 5.035
201512 4.974 99.792 6.725
201603 3.702 100.470 4.972
201606 18.171 101.688 24.111
201609 1.735 101.861 2.298
201612 4.764 101.863 6.310
201703 0.222 102.862 0.291
201706 0.041 103.349 0.054
201709 0.037 104.136 0.048
201712 0.023 104.011 0.030
201803 0.000 105.290 0.000
201806 0.000 106.317 0.000
201809 0.000 106.507 0.000
201812 1.207 105.998 1.536
201903 0.008 107.251 0.010
201906 0.009 108.070 0.011
201909 0.000 108.329 0.000
201912 3.809 108.420 4.740
202003 0.000 108.902 0.000
202006 0.000 108.767 0.000
202009 1.323 109.815 1.626
202012 3.322 109.897 4.079
202103 2.994 111.754 3.615
202106 4.868 114.631 5.730
202109 6.363 115.734 7.418
202112 7.621 117.630 8.742
202203 7.996 121.301 8.894
202206 7.934 125.017 8.563
202209 4.065 125.227 4.380
202212 3.291 125.222 3.546
202303 1.162 127.348 1.231
202306 1.026 128.729 1.075
202309 1.270 129.860 1.320
202312 1.561 129.419 1.627
202403 1.079 131.776 1.105
202406 1.880 132.554 1.914
202409 0.018 133.029 0.018
202412 -0.029 133.157 -0.029
202503 0.042 134.927 0.042

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cartesian Therapeutics  (NAS:RNAC) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Cartesian Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Cartesian Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cartesian Therapeutics Business Description

Traded in Other Exchanges
Address
7495 New Horizon Way, Frederick, MD, USA, 21703
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
Executives
Timothy A Springer director 36 WOODMAN ROAD, CHESTNUT HILL MA 02467
Blaine Davis officer: Chief Financial Officer C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Carsten Brunn director, officer: President & CEO C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Timothy C Barabe director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Peter G Traber officer: Chief Medical Officer 430 THAMER LANE, HOUSTON TX 77025
Takashi Kei Kishimoto officer: Chief Scientific Officer 480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472
Lloyd P. Johnston officer: COO and SVP, R&D 480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472
Carrie Smith Cox director SCHERING-PLOUGH CORPORATION, 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Kevin Tan officer: Chief Financial Officer 20 HICKORY ROAD, WELLESLEY MA 02482
Nishan M Desilva director 11119 NORTH TORREY PINES RD STE 200, LA JOLLA CA 92037
Ann K. Donohue officer: VP Finance C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, BUILDING ONE, WATERTOWN MA 02472
Bradford D. Dahms officer: Chief Financial Officer C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Goran Ando director
Scott Dunseth Myers director C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Elona Esq. Kogan officer: General Counsel C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065